Erin Colgan
Treasurer presso Massachusetts Biotechnology Education Foundation
Patrimonio netto: 40 987 $ in data 30/04/2024
Posizioni attive di Erin Colgan
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Massachusetts Biotechnology Education Foundation
 Massachusetts Biotechnology Education Foundation Miscellaneous Commercial ServicesCommercial Services Massachusetts Biotechnology Education Foundation supports science and biotechnology education in Massachusetts through school programs and workforce training. The company was founded in 2001 and is headquartered in Cambridge, MA. | Treasurer | - | - |
Storia della carriera di Erin Colgan
Precedenti posizioni note di Erin Colgan
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| SENSEI BIOTHERAPEUTICS, INC. | Direttore Amministrativo | 01/07/2020 | 01/12/2021 |
| Direttore Finanziario/CFO | 01/01/2022 | 10/04/2024 | |
Intarcia Therapeutics, Inc.
 Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Corporate Officer/Principal | 01/08/2019 | 01/06/2020 |
| VERTEX PHARMACEUTICALS INCORPORATED | Corporate Officer/Principal | 01/08/2010 | 01/08/2019 |
Formazione di Erin Colgan
| University of Massachusetts | Undergraduate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 6 |
Posizioni
| Corporate Officer/Principal | 2 |
| Chief Administrative Officer | 1 |
| Director of Finance/CFO | 1 |
Settori
| Health Technology | 4 |
| Consumer Services | 2 |
| Commercial Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| SENSEI BIOTHERAPEUTICS, INC. | Health Technology |
| VERTEX PHARMACEUTICALS INCORPORATED | Health Technology |
| Aziende private | 2 |
|---|---|
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Health Technology |
Massachusetts Biotechnology Education Foundation
Massachusetts Biotechnology Education Foundation Miscellaneous Commercial ServicesCommercial Services Massachusetts Biotechnology Education Foundation supports science and biotechnology education in Massachusetts through school programs and workforce training. The company was founded in 2001 and is headquartered in Cambridge, MA. | Commercial Services |
- Borsa valori
- Insiders
- Erin Colgan
- Esperienza
